Highlights

  • ResMed reported record fourth-quarter Revenue of US$1.5 billion, up 9% year on year.
  • Non-GAAP diluted EPS increased 16% to US$2.95.
  • The company returned about US$1 billion to shareholders in FY26 via dividends and buybacks.
  • Sleep-device Demand and Margin performance remain central to the outlook.

ResMed Inc (ASX:RMD) is drawing attention from income investors following a record quarter that underpinned a substantial return of Capital to shareholders. The company posted fourth-quarter revenue of US$1.5 billion, up 9% year on year, while non-GAAP Diluted Earnings per Share rose 16% to US$2.95.

Across FY26, ResMed returned approximately US$1 billion to shareholders through dividends and share repurchases, a scale of capital return that keeps the stock firmly on the radar for those tracking ASX-listed distributions.

Ex-Dividend Snapshot

Code

Company

Days

Ex-Date

Amount

Franking

Type

Pay Date

RMD

Resmed Inc

5

19 Aug

$0.066

0%

Final

24 Sep 2026

Company Snapshot

ResMed designs and manufactures medical devices and cloud-connected software used in the treatment of sleep apnoea and other respiratory conditions. Its core products include CPAP devices and masks used by patients managing obstructive sleep apnoea.

The company has also built out a digital health business, offering software-as-a-service solutions used by healthcare providers to manage patient care, adding a recurring-revenue dimension to its traditional device sales.

FY26 Results at a Glance

ResMed's fourth-quarter revenue of US$1.5 billion represented 9% year-on-year growth, while non-GAAP diluted EPS climbed 16% to US$2.95. Growth was supported by ongoing demand for sleep and respiratory devices across the company's global markets.

The strong result contributed to a full-year capital return of about US$1 billion to shareholders, comprising both Dividend payments and share buybacks, reflecting the cash-generative nature of the underlying business.

Income Snapshot

ResMed's latest declared dividend is 6.6 cents per CDI, unfranked, with an ex-dividend date of 19 August 2026 and payment scheduled for 24 September 2026.

As a US-domiciled company with ASX-listed CHESS Depositary Interests (CDIs), ResMed's distributions are typically unfranked, which is an important distinction for Australian income investors comparing yields across the market.

Points on Investors' Radar

Investors in ResMed commonly track device shipment volumes, subscriber growth in its digital health software business, gross margin trends and the pace of capital returned via dividends and buybacks.

Currency movements between the US dollar and other operating currencies, along with regulatory developments in key healthcare markets, are additional factors that can influence reported results.

Looking Ahead

With record quarterly revenue and double-digit EPS growth, ResMed's longer-term trajectory will likely continue to be shaped by global demand for sleep and respiratory care solutions, alongside the expansion of its software offerings.

Margin performance and continued capital discipline are expected to remain relevant themes for investors assessing the company's outlook beyond the current period.

Summary

ResMed's record results, double-digit EPS growth and roughly US$1 billion in FY26 Shareholder returns keep the stock on the radar heading into its upcoming ex-dividend date.

As dividend amounts and franking can change between periods, investors should confirm the latest details through ResMed's official announcements.